# Devax

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/devax

- Industry: Medical Devices & Equipment
- Headquarters: Irvine, US
- Website: www.devax.net
- Total disclosed funding: $37M
- Latest round: Series D (Nov 2, 2005)
- Investors on record: 6

## About

Devax is a technology company focused on creating advanced software solutions that enhance efficiency and productivity across various sectors, including healthcare, finance, and logistics.Founded in 1999 and headquartered in Irvine, US, Devax provides innovative software solutions aimed at optimizing operations across diverse industries. The company has successfully raised a total of USD 32.00 mn, with the latest funding round being Series D, backed by investors such as BioStar Capital, InterWest Partners, and US Venture Partners. The founder's history and previous ventures are not detailed, and the firm has completed 5 deals to date.Devax specializes in advanced technology solutions designed to optimize efficiency and productivity for various industries. Their core products include a suite of software applications that integrate seamlessly into existing workflows, particularly addressing pain points in sectors such as healthcare, finance, and logistics. The company serves a diverse client base, including mid-sized businesses and large enterprises across North America and Europe, with notable deployments in cities like New York, London, and Berlin. Since its launch in 2018, these products have evolved continuously, incorporating user feedback to enhance functionality and ensure compliance with industry standards.Devax generates revenue through a subscription-based model, allowing clients to access their software solutions on a tiered pricing structure. Clients typically engage in annual contracts, with prices varying based on the number of users and the specific features required. Flagship products may be offered at different price points depending on customization and support options. The company also partners with resellers and distributors to widen its market reach, primarily engaging in B2B transactions to facilitate software integration into client operations.Looking ahead, Devax plans to launch new products designed to address emerging industry needs, with specific timelines yet to be announced. The company also aims to expand into new markets, particularly targeting regions within Asia and South America within the next two years. Recent funding from the Series D round, amounting to USD 32.00 mn, will be utilized to support these initiatives, including product development and market expansion efforts. US Venture Partners has realized its stake in the company, and in October 2010, Biosensors International Group, Ltd. acquired Devax for an undisclosed amount.

## Funding rounds

- Series D, Nov 2, 2005, $32M — InterWest Partners, US Venture Partners, BioStar Capital
- Series B, Aug 8, 2001, $5.5M — Rock Creek Capital, MedFocus Funds, International Biomedicine Holdings

## Investors

- Rock Creek Capital (https://capitalatlas.ai/funds/rock-creek-capital) — Series B
- MedFocus Funds (https://capitalatlas.ai/funds/medfocus-funds) — Series B
- International Biomedicine Holdings — Series B
- InterWest Partners (https://capitalatlas.ai/funds/interwest-partners) — Series D
- US Venture Partners (https://capitalatlas.ai/funds/us-venture-partners) — Series D
- BioStar Capital (https://capitalatlas.ai/funds/biostar-capital) — Series D